Sulfonylureas inhibit cytokine-induced eosinophil survival and activation

Jennifer L. Bankers-Fulbright, Gail M. Kephart, David A. Loegering, Annabel L. Bradford, Shinji Okada, Hirohito Kita, Gerald J. Gleich

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Eosinophils play a key role in the pathogenesis of asthma and other allergic inflammatory diseases. We have previously shown that treatment of eosinophils with lidocaine preferentially inhibits IL-5-induced survival. This inhibition cannot be overcome by increasing concentrations of IL-5 and is not due to the blocking of Na+ channels by lidocaine. Here we report that one class of K+ channel blockers, the sulfonylureas, inhibits eosinophil survival in a manner similar to lidocaine. The sulfonylurea glyburide inhibits eosinophil survival even at high concentrations of IL-5. In contrast, increasing concentrations of IL-3 or granulocyte-macrophage CSF overcome glyburide inhibition. Glyburide also blocks cytokine-induced eosinophil superoxide production. Similar results were seen with the sulfonylureas tolbutamide and glipizide. Interestingly, the effects of glyburide are not antagonized by the ATP-sensitive K+ channel openers cromakalim, pinacidil, or diazoxide. Although Scatchard analysis of [3H]glyburide binding to eosinophil membranes indicated that the high affinity sulfonylurea receptor (SUR1) is not present on eosinophils, human eosinophils do express mRNA homologous to the sulfonylurea receptor family, in keeping with the presence of a sulfonylurea receptor. Finally, coculture of eosinophils with combinations of glyburide, lidocaine, and dexamethasone resulted in synergistic inhibition of cytokine-mediated eosinophil survival and superoxide production. These results have intriguing clinical implications for the treatment of eosinophil-associated diseases.

Original languageEnglish (US)
Pages (from-to)5546-5553
Number of pages8
JournalJournal of Immunology
Volume160
Issue number11
StatePublished - Jun 1 1998

Fingerprint

Eosinophils
Cytokines
Glyburide
Sulfonylurea Receptors
Lidocaine
Interleukin-5
Superoxides
Glipizide
Pinacidil
Cromakalim
Diazoxide
Tolbutamide
Interleukin-3
Coculture Techniques
Granulocytes
Dexamethasone
Asthma
Adenosine Triphosphate
Macrophages
Messenger RNA

ASJC Scopus subject areas

  • Immunology

Cite this

Bankers-Fulbright, J. L., Kephart, G. M., Loegering, D. A., Bradford, A. L., Okada, S., Kita, H., & Gleich, G. J. (1998). Sulfonylureas inhibit cytokine-induced eosinophil survival and activation. Journal of Immunology, 160(11), 5546-5553.

Sulfonylureas inhibit cytokine-induced eosinophil survival and activation. / Bankers-Fulbright, Jennifer L.; Kephart, Gail M.; Loegering, David A.; Bradford, Annabel L.; Okada, Shinji; Kita, Hirohito; Gleich, Gerald J.

In: Journal of Immunology, Vol. 160, No. 11, 01.06.1998, p. 5546-5553.

Research output: Contribution to journalArticle

Bankers-Fulbright, JL, Kephart, GM, Loegering, DA, Bradford, AL, Okada, S, Kita, H & Gleich, GJ 1998, 'Sulfonylureas inhibit cytokine-induced eosinophil survival and activation', Journal of Immunology, vol. 160, no. 11, pp. 5546-5553.
Bankers-Fulbright JL, Kephart GM, Loegering DA, Bradford AL, Okada S, Kita H et al. Sulfonylureas inhibit cytokine-induced eosinophil survival and activation. Journal of Immunology. 1998 Jun 1;160(11):5546-5553.
Bankers-Fulbright, Jennifer L. ; Kephart, Gail M. ; Loegering, David A. ; Bradford, Annabel L. ; Okada, Shinji ; Kita, Hirohito ; Gleich, Gerald J. / Sulfonylureas inhibit cytokine-induced eosinophil survival and activation. In: Journal of Immunology. 1998 ; Vol. 160, No. 11. pp. 5546-5553.
@article{0f86a6d7ef244d5db0707ade19199766,
title = "Sulfonylureas inhibit cytokine-induced eosinophil survival and activation",
abstract = "Eosinophils play a key role in the pathogenesis of asthma and other allergic inflammatory diseases. We have previously shown that treatment of eosinophils with lidocaine preferentially inhibits IL-5-induced survival. This inhibition cannot be overcome by increasing concentrations of IL-5 and is not due to the blocking of Na+ channels by lidocaine. Here we report that one class of K+ channel blockers, the sulfonylureas, inhibits eosinophil survival in a manner similar to lidocaine. The sulfonylurea glyburide inhibits eosinophil survival even at high concentrations of IL-5. In contrast, increasing concentrations of IL-3 or granulocyte-macrophage CSF overcome glyburide inhibition. Glyburide also blocks cytokine-induced eosinophil superoxide production. Similar results were seen with the sulfonylureas tolbutamide and glipizide. Interestingly, the effects of glyburide are not antagonized by the ATP-sensitive K+ channel openers cromakalim, pinacidil, or diazoxide. Although Scatchard analysis of [3H]glyburide binding to eosinophil membranes indicated that the high affinity sulfonylurea receptor (SUR1) is not present on eosinophils, human eosinophils do express mRNA homologous to the sulfonylurea receptor family, in keeping with the presence of a sulfonylurea receptor. Finally, coculture of eosinophils with combinations of glyburide, lidocaine, and dexamethasone resulted in synergistic inhibition of cytokine-mediated eosinophil survival and superoxide production. These results have intriguing clinical implications for the treatment of eosinophil-associated diseases.",
author = "Bankers-Fulbright, {Jennifer L.} and Kephart, {Gail M.} and Loegering, {David A.} and Bradford, {Annabel L.} and Shinji Okada and Hirohito Kita and Gleich, {Gerald J.}",
year = "1998",
month = "6",
day = "1",
language = "English (US)",
volume = "160",
pages = "5546--5553",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - Sulfonylureas inhibit cytokine-induced eosinophil survival and activation

AU - Bankers-Fulbright, Jennifer L.

AU - Kephart, Gail M.

AU - Loegering, David A.

AU - Bradford, Annabel L.

AU - Okada, Shinji

AU - Kita, Hirohito

AU - Gleich, Gerald J.

PY - 1998/6/1

Y1 - 1998/6/1

N2 - Eosinophils play a key role in the pathogenesis of asthma and other allergic inflammatory diseases. We have previously shown that treatment of eosinophils with lidocaine preferentially inhibits IL-5-induced survival. This inhibition cannot be overcome by increasing concentrations of IL-5 and is not due to the blocking of Na+ channels by lidocaine. Here we report that one class of K+ channel blockers, the sulfonylureas, inhibits eosinophil survival in a manner similar to lidocaine. The sulfonylurea glyburide inhibits eosinophil survival even at high concentrations of IL-5. In contrast, increasing concentrations of IL-3 or granulocyte-macrophage CSF overcome glyburide inhibition. Glyburide also blocks cytokine-induced eosinophil superoxide production. Similar results were seen with the sulfonylureas tolbutamide and glipizide. Interestingly, the effects of glyburide are not antagonized by the ATP-sensitive K+ channel openers cromakalim, pinacidil, or diazoxide. Although Scatchard analysis of [3H]glyburide binding to eosinophil membranes indicated that the high affinity sulfonylurea receptor (SUR1) is not present on eosinophils, human eosinophils do express mRNA homologous to the sulfonylurea receptor family, in keeping with the presence of a sulfonylurea receptor. Finally, coculture of eosinophils with combinations of glyburide, lidocaine, and dexamethasone resulted in synergistic inhibition of cytokine-mediated eosinophil survival and superoxide production. These results have intriguing clinical implications for the treatment of eosinophil-associated diseases.

AB - Eosinophils play a key role in the pathogenesis of asthma and other allergic inflammatory diseases. We have previously shown that treatment of eosinophils with lidocaine preferentially inhibits IL-5-induced survival. This inhibition cannot be overcome by increasing concentrations of IL-5 and is not due to the blocking of Na+ channels by lidocaine. Here we report that one class of K+ channel blockers, the sulfonylureas, inhibits eosinophil survival in a manner similar to lidocaine. The sulfonylurea glyburide inhibits eosinophil survival even at high concentrations of IL-5. In contrast, increasing concentrations of IL-3 or granulocyte-macrophage CSF overcome glyburide inhibition. Glyburide also blocks cytokine-induced eosinophil superoxide production. Similar results were seen with the sulfonylureas tolbutamide and glipizide. Interestingly, the effects of glyburide are not antagonized by the ATP-sensitive K+ channel openers cromakalim, pinacidil, or diazoxide. Although Scatchard analysis of [3H]glyburide binding to eosinophil membranes indicated that the high affinity sulfonylurea receptor (SUR1) is not present on eosinophils, human eosinophils do express mRNA homologous to the sulfonylurea receptor family, in keeping with the presence of a sulfonylurea receptor. Finally, coculture of eosinophils with combinations of glyburide, lidocaine, and dexamethasone resulted in synergistic inhibition of cytokine-mediated eosinophil survival and superoxide production. These results have intriguing clinical implications for the treatment of eosinophil-associated diseases.

UR - http://www.scopus.com/inward/record.url?scp=0032101945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032101945&partnerID=8YFLogxK

M3 - Article

C2 - 9605159

AN - SCOPUS:0032101945

VL - 160

SP - 5546

EP - 5553

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -